Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies
- Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream to treat atopic dermatitis (AD).
- Data presented at the American Academy of Dermatology Virtual Meeting Experience 2021 showed Ruxolitinib demonstrated greater improvement in all analyzed efficacy endpoints than vehicle.
- A subsequent analysis of a subset of patients found higher clinical responses with ruxolitinib cream versus vehicle.
- At Week 8, more patients achieved treatment success with ruxolitinib cream 0.75% and ruxolitinib cream 1.5% versus vehicle (50.0% and 59.4% versus 0%, respectively).
- Patients who applied ruxolitinib cream 0.75% and ruxolitinib cream 1.5% versus vehicle achieved improvement in eczema severity at Week 8.
- At Week 8, more patients achieved improvement in itch with ruxolitinib cream 0.75% and ruxolitinib cream 1.5% versus vehicle (50.0% and 61.1% versus 27.3%).
- Incyte also announced updated data at Week 104 from the Phase 2 study with ruxolitinib cream in adult patients with vitiligo.
- New data showed continuous improvements in facial and total body repigmentation.
- Separately, an exploratory analysis evaluated the maintenance of repigmentation among patients. 75% of patients maintained total body repigmentation, and 81.3 % of patients held facial repigmentation during a follow-up duration of one to six months.
- Price Action: INCY shares are up 0.8% at $84.88 on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: atopic dermatitis Briefs Phase 3 TrialBiotech News Health Care General
